An interventional study of High-Dose Taurine Supplementation (6g) and Medium-Dose Taurine Supplementation (4g) in Exercise Performance in Extreme Environments, sponsored by Xiaodong Cheng. Completed at 1 site in China. Open to participants aged 20 Days to 26 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by Xiaodong Cheng · Not applicable, Interventional, and Basic science
This study is designed to evaluate the effects of acute pre-exercise taurine supplementation at different doses on the performance of college students during exhaustive exercise and subsequent repetitive sprint (RS) activities in a high-temperature, high-humidity environment. Sixteen college students (8 male, 8 female) will participate in a single-blind, randomized, crossover-controlled trial. Participants will be divided into four groups: high-dose taurine (6g), medium-dose taurine (4g), low-dose taurine (1g), and placebo. Key performance metrics such as peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump height, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE) will be measured.
The objective of this study is to assess how taurine supplementation influences exercise performance under these challenging environmental conditions. This study will help to better understand taurine's potential effects on exercise performance and contribute to nutritional strategies for athletes exposed to extreme conditions.
This study is designed to evaluate the effects of taurine supplementation on exercise performance under extreme environmental conditions of high temperature and high humidity. The primary goal is to investigate whether taurine supplementation can enhance performance during exhaustive exercise and subsequent repetitive sprints (RS). Sixteen college students (8 male, 8 female) will participate in a single-blind, randomized, crossover-controlled trial. Participants will be divided into four groups receiving either high-dose (6g), medium-dose (4g), low-dose (1g) taurine supplementation, or placebo.
The study will involve a protocol with exhaustive exercise followed by six repetitive sprints. Performance metrics such as peak power (PP), mean power (MP), and fatigue index (FI) will be recorded. Additionally, physiological parameters, including heart rate (HR) and blood lactate (BLA), as well as subjective measures like ratings of perceived exertion (RPE), will be monitored. A standardized measurement protocol will be used to ensure consistency and accuracy across trials.
478 studies on the registry are indexed under Hyperthermia; 92 are open to participants now.
This study's enrollment of 16 is below the median of 60 across 365 interventional studies indexed under Hyperthermia.
Browse Hyperthermia studies →Xiaodong Cheng is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria :
Participants in this arm will receive taurine supplementation at a high dose of 6g, dissolved in water, administered 30 minutes prior to exercise. High-Dose Taurine Supplementation (6g)
Dietary Supplement: High-Dose Taurine Supplementation (6g)
Participants in this study arm will receive a medium dose of taurine supplementation (4g) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This intervention aims to evaluate the effects of medium-dose taurine on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure key parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of a moderate taurine dosage compared to the high-dose and low-dose groups.
Dietary Supplement: Medium-Dose Taurine Supplementation (4g)
Participants in this study arm will receive a low dose of taurine supplementation (1g) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This intervention aims to assess the effects of low-dose taurine on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure multiple parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of a smaller taurine dosage compared to the medium-dose and high-dose groups.
Dietary Supplement: Low-Dose Taurine Supplementation (1g)
Participants in this study arm will receive a placebo (inactive substance) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This group serves as the control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure key parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of an inactive placebo, which contains no taurine, to compare against the taurine intervention arms.
Dietary Supplement: Placebo (0g Taurine)
Participants will receive taurine supplementation at a high dose of 6g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of high-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
Participants will receive taurine supplementation at a medium dose of 4g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of medium-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
Participants will receive taurine supplementation at a low dose of 1g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of low-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
Participants will receive a placebo, consisting of an inactive substance (0g taurine). The placebo will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention serves as a control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
Change from Baseline in Peak Power (Watts)
Description: Maximum power output during each of the 6 sprints, measured using a cycle ergometer. Method of Assessment: Power output will be recorded for each sprint, and the peak value will be identified.
Time frame: Measured at the end of each sprint on Day 1 and Day 7.
Change from Baseline in Mean Power (Watts)
Description: Average power output across all 6 sprints, reflecting sustained anaerobic performance. Method of Assessment: Power output will be averaged across all sprints.
Time frame: Measured after all 6 sprints on Day 1 and Day 7.
Change from Baseline in Fatigue Index (%/s)
Description: Rate of decline in power output across the sprints, representing fatigue resistance. Method of Assessment: The decline in power output will be calculated as the difference between the first and last sprint, divided by the time interval.
Time frame: Measured across all 6 sprints on Day 1 and Day 7.
Change from Baseline in Exhaustion Time (seconds or minutes)
Description: The duration participants can sustain exercise before reaching volitional exhaustion. Method of Assessment: Time will be recorded from the start of exercise until the participant reaches exhaustion.
Time frame: Measured at the point of exhaustion during exhaustive exercise on Day 1 and Day 7.
Change from Baseline in Blood Lactate Levels (mmol/L)
Description: Blood lactate levels will be measured to evaluate metabolic stress and recovery during exercise. Method of Assessment: Blood samples will be collected at designated time points during recovery to assess lactate accumulation and clearance.
Time frame: Measured at baseline (pre-exercise), immediately after exercise, and at specific recovery intervals on Day 1 and Day 7.
Change from Baseline in Ratings of Perceived Exertion (RPE)
Description: Participants' perceived physical and mental exertion will be assessed using the Borg Rating of Perceived Exertion Scale. Method of Assessment: Participants will rate their exertion on a scale from 6 (no exertion at all) to 20 (maximal exertion).
Time frame: Measured continuously during exhaustive exercise and repetitive sprint activity on Day 1 and Day 7.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — The individual participant data (IPD) from this study, including anonymized performance metrics, physiological responses, and metabolic data, will be shared with other researchers upon reasonable request. Data will be provided in accordance with applicable ethical and regulatory guidelines to ensure the privacy and confidentiality of study participants. Requests for data access can be made by contacting the principal investigator, Cheng Xiaodong, at chengxiaodong@xiyi.edu.cn.
Supporting information: Sap
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiaodong Cheng